Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Using two instead of three or four drugs could potentially lead to cost savings in the billions.
Only a small proportion of people who start treatment very early might be eligible for dolutegravir monotherapy.
Once-daily Biktarvy, long-acting injectable Cabenuva and two-drug combos containing dolutegravir can keep HIV in check for years.
People starting on integrase inhibitors were no more likely to have heart attacks, strokes or cardiovascular procedures.
SNL is lazy and lame when it comes to jokes about STIs, so it’s no surprise that homophobia was the center of their Dovato HIV ad roast.
People who saw substantial CD4 T-cell gains during the first two years after diagnosis had better outcomes.
A two-drug combination of dolutegravir and lamivudine can be a good option for people starting rapid HIV treatment.
Study shows just one snapshot of the impact of COVID-19 on the health and access to care among people living with HIV.
Compared to other common HIV treatments, dolutegravir-based regimens maintained viral suppression even without perfect adherence.
Two-drug combo of dolutegravir and lamivudine suppresses HIV in newly diagnosed people.
The small single-site study will need to be replicated in a larger group of adolescents.
Many participants on two-drug regimens had more treatment under their belt and more chronic conditions.
However, all integrase inhibitors were associated with similar weight gain.
People whose viral load rebounds on Tivicay may not need to switch medications.
ViiV’s two-drug Dovato also boasted a high genetic barrier to the development of viral resistance.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.